Drug Trial Radar · NCT03431350
A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
136
Actual
Start
Mar 2, 2018
Primary completion
Aug 31, 2021
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Feb 13, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to: a) establish the recommended phase 2 dose (RP2D) and to evaluate the antitumor activity and safety of niraparib combination therapies (Combinations 1 and 2) and b) to determine the relative bioavailability of niraparib and abiraterone acetate (AA) in combination (Combination 3) in participants with metastatic castration-resistant prostate cancer (mCRPC).
Conditions
- Prostatic Neoplasms, Castration-Resistant
Interventions
Niraparib 200 mgDrug
Participants will receive niraparib 200 mg orally.
Cetrelimab 240 mgDrug
Participants will receive cetrelimab 240 mg IV every 2 weeks.
Cetrelimab 480 mgDrug
Participants will receive cetrelimab 480 mg IV every 4 weeks.
Abiraterone acetate 1000 mgDrug
Participants will receive AA 1000 mg orally.
Prednisone 5 mgDrug
Participants will receive prednisone 5 mg orally.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Combination 1: Part 1: Number of Participants With Specified ToxicityTime frame: Cycle 1 (28 days)
- Combination 1: Part 2: Objective Response Rate (ORR)Time frame: Up to 37 months
- Combination 2: Composite Response Rate (RR)Time frame: Up to 31 months
- Combination 1: Part 2: Number of Participants With Adverse Events (AEs)Time frame: Up to 37 months
- Combination 2: Number of Participants With Adverse Events (AEs)Time frame: Up to 31 months
- Combination 1: Part 2: Number of Participants With Adverse Events (AEs) of Grade >=3 SeverityTime frame: Up to 37 months
- Combination 2: Number of Participants With Adverse Events (AEs) of Grade >=3 SeverityTime frame: Up to 31 months
- Combination 3: Maximum Observed Plasma Concentration (Cmax) of Niraparib and Abiraterone Acetate After a Single DoseTime frame: Pre-dose, 30 min, 1 hour (hr), 1.5 hr, 2hr, 3 hr, 4 hr, 6 hr, 8 hr, 10 hr, 24 hr, 48 hr, 72 hr, and 168 hr post dose on Day 1
- Combination 3: Maximum Observed Plasma Concentration (Cmax) of Niraparib Normalized by the Dose(Niraparib) (Cmax/Dose) of Niraparib Administered With AA After a Single DoseTime frame: Pre-dose, 30 min, 1 hour (hr), 1.5 hr, 2hr, 3 hr, 4 hr, 6 hr, 8 hr, 10 hr, 24 hr, 48 hr, 72 hr, and 168 hr post dose on Day 1
- Combination 3: Area Under the Plasma Concentration-Time Curve From Time Zero to 168 Hours (AUC [0-168hr]) of Niraparib Administered With AA After a Single DoseTime frame: Pre-dose, 30 min, 1 hour (hr), 1.5 hr, 2hr, 3 hr, 4 hr, 6 hr, 8 hr, 10 hr, 24 hr, 48 hr, 72 hr, and 168 hr post dose on Day 1
- Combination 3: Area Under the Plasma Concentration-Time Curve for Niraparib From Time Zero to 168 Hours (AUC [0-168 Hours]/Dose) of Niraparib Administered With AA After a Single DoseTime frame: Pre-dose, 30 min, 1 hour (hr), 1.5 hr, 2hr, 3 hr, 4 hr, 6 hr, 8 hr, 10 hr, 24 hr, 48 hr, 72 hr, and 168 hr post dose on Day 1
Locations
50 sites in 7 countries. Site status is shown where the registry gives one.
Urological Associates of Southern Arizona, P.C.
Tucson, Arizona
The Urology Center of Colorado
Denver, Colorado
Mayo Clinic - Division Of Hematology/oncology
Jacksonville, Florida
First Urology, PSC
Jeffersonville, Indiana
Chesapeake Urology Research Associates
Towson, Maryland
Michigan Institute of Urology
Troy, Michigan
New York Oncology Hematology
Albany, New York
Memorial Sloan Kettering Cancer Center 1
Harrison, New York
Memorial Sloan Kettering Cancer Center
New York, New York
Thomas Jefferson University
Philadelphia, Pennsylvania
University of Pittsburgh Medical Center (UPMC)
Pittsburgh, Pennsylvania
MUSC-Hollings Cancer Center
Charleston, South Carolina
Carolina Urologic Research Center
Myrtle Beach, South Carolina
Urology Associates
Nashville, Tennessee
Houston Metro Urology
Houston, Texas
The University of Texas MD Anderson Cancer Center
Houston, Texas
Utah Cancer Specialists
Salt Lake City, Utah
Urology of Virginia, PLCC
Virginia Beach, Virginia
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin
OLV Ziekenhuis Aalst
Aalst, Belgium
ZNA Middelheim
Antwerp, Belgium
ULB Hôpital Erasme
Brussels, Belgium
Universitair Ziekenhuis Gent
Ghent, Belgium
Az Groeninge
Kortrijk, Belgium
Centre Hospitalier Universitaire de Liege Domaine Universitaire du Sart Tilman
Liège, Belgium
Southern Alberta Institute of Urology / Prostate Cancer Centre
Calgary, Alberta, Canada
British Columbia Cancer Agency
Vancouver, British Columbia, Canada
Princess Margaret Cancer Centre University Health Network
Toronto, Ontario, Canada
Centre de Recherche du CHUM
Montreal, Quebec, Canada
Asaf Harofe Medical Center
Beer Yaakov, Israel
Soroka Hospital
Beersheba, Israel
Rambam Medical Center
Haifa, Israel
Rabin Medical Center
Petah Tikva, Israel
Sheba Medical Center Tel Hashomer
Ramat Gan, Israel
Azienda Ospedaliera Universitaria Careggi di Firenze
Florence, Italy
Azienda Ospedaliera ''Vito Fazzi''
Lecce, Italy
ASST Grande Ospedale Metropolitano Niguarda
Milan, Italy
IRCCS-Fondazione Pascale
Naples, Italy
UOC Oncologia Ospedale Provinciale di Macerata
Province of Macerata, Italy
Hosp. de La Santa Creu I Sant Pau
Barcelona, Spain
Showing 40 of 50 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.